Evidence map›Paper›PMID 30254071›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2018

Methylation-derived Neutrophil-to-Lymphocyte Ratio and Lung Cancer Risk in Heavy Smokers.

Laurie Grieshober, Stefan Graw, Matt J Barnett, Mark D Thornquist, Gary E Goodman, Chu Chen, Devin C Koestler, Carmen J Marsit, Jennifer A Doherty

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. White Blood Cell Count, Neutrophil-to-Lymphocyte Ratio, and Incident Cancer in the UK Biobank.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Hypermethylation ofMolecular therapy. Nucleic acids · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laurie GrieshoberDepartment of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Stefan GrawDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas.
Matt J BarnettProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Mark D ThornquistProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Gary E GoodmanProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Chu ChenProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Devin C Koestler *Department of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas.
Carmen J Marsit *Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Jennifer A Doherty *Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. jen.doherty@hci.utah.edu.

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Mentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Douglas E Wright · 2012 to 2026
$63.0M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
THE CAROTENE AND RETINOL EFFICACY TRIAL (CARET)U01CA063673 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 1994 to 2006
$13.0M
Infrastructure Support and Pilot Tissue Collection for the CARET BiorepositoryU01CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEUHOUSER, MARIAN L · 2018 to 2022
$2.9M
INFRASRUCTURE SUPPORT AND DATA ENHANCEMENTS FOR THE CARET BIOREPOSITORYUM1CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 2013 to 2017
$2.8M
Telomeres and lung cancer incidence and survivalR01CA151989 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DOHERTY, JENNIFER A. · 2011 to 2014
$2.4M
MOLECULAR EPIDEMIOLOGY OF LUNG CANCERR01CA111703 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHEN, CHU · 2006 to 2010
$2.2M
NRSA Training CoreTL1TR002540 · NCATS · UNIVERSITY OF UTAH · PI FAGERLIN, ANGELA, FAIRFAX, KEKE CELESTE · 2018 to 2022
$1.6M
NCATS NIH HHS TL1 TR002540NCI NIH HHS P30 CA042014NCI NIH HHS P30 CA168524NCI NIH HHS R01 CA111703NCI NIH HHS R01 CA151989NCI NIH HHS U01 CA063673NCI NIH HHS U01 CA167462NCI NIH HHS UM1 CA167462NIGMS NIH HHS P20 GM103418
6 · The paper itself

Abstract

The neutrophil-to-lymphocyte ratio (NLR) is a biomarker that indicates systemic inflammation and can be estimated using array-based DNA methylation data as methylation-derived NLR (mdNLR). We assessed the relationship between prediagnosis mdNLR and lung cancer risk in a nested case-control study in the β-Carotene and Retinol Efficacy Trial (CARET) of individuals at high risk for lung cancer due to heavy smoking or substantial occupational asbestos exposure. We matched 319 incident lung cancer cases to controls based on age at blood draw, smoking, sex, race, asbestos, enrollment year, and time at risk. We computed mdNLR using the ratio of predicted granulocyte and lymphocyte proportions derived from DNA methylation signatures in whole blood collected prior to diagnosis (median 4.4 years in cases). Mean mdNLR was higher in cases than controls (2.06 vs. 1.86,

Indexed as

LymphocytesNeutrophilsAgedAsbestosbeta CaroteneCarcinoma, Non-Small-Cell LungCase-Control StudiesDiterpenesDNA MethylationFemaleHumansInflammationLung NeoplasmsLymphocyte CountMaleMiddle AgedAsbestosbeta CaroteneDiterpenesretinol palmitateRetinyl EstersVitamin A

Identifiers

PMID30254071
PMCPMC6214718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.